DrugsNews.net

Drugs Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Neurologia

Antibiotics: Amoxicillin use during infancy may be linked to tooth enamel defects


Use of the antibiotic Amoxicillin during infancy appears to be linked to tooth enamel defects in permanent teeth.

The study is published in the Archives of Pediatrics and Adolescent Medicine.

Dental fluorosis, a result of exposure to excessive fluoride during enamel formation, is one of the most common developmental enamel defects.

The clinical signs range from barely noticeable white flecks, to pits and brown stains.

Amoxicillin is one of the most common antibiotics used among pediatric patients, mainly for treatment of otitis media.
There has been some evidence that Amoxicillin use could be associated with dental enamel defects, and, the authors suggest, even a small effect on dental enamel could have a significant effect on the public's dental health because of the widespread use of Amoxicillin.

Liang Hong, of the University of Iowa, Iowa City ( now at the University of Missouri, Kansas City ), and colleagues assessed the association between dental fluorosis and Amoxicillin use during early childhood.

The researchers analyzed data from the Iowa Fluoride Study, a prospective study investigating fluoride exposures, biological and behavioral factors, and children's dental health. They followed 579 participants from birth to 32 months, using questionnaires every three to four months to gather information on fluoride intake and Amoxicillin use.

" The results show that Amoxicillin use during early infancy seems to be linked to dental fluorosis on both permanent first molars and maxillary central incisors," the authors report. " Duration of Amoxicillin use was related to the number of early-erupting permanent teeth with fluorosis."

By the age of one year, three-quarters of the subjects had used Amoxicillin. By 32 months, 91 percent of participants had used Amoxicillin. " Overall, 24 percent had fluorosis on both maxillary central incisors," the authors write.

Amoxicillin use from three to six months doubled the risk of dental fluorosis. " The significantly elevated risk for dental fluorosis associated with amoxicillin use during early infancy was found at all levels of statistical analyses, even after controlling for other potential risk factors, such as fluoride intake, otitis media infections, and breastfeeding," the authors report.

The authors emphasize that additional laboratory and clinical studies -- including controlled animal studies with specified Amoxicillin dosages, chemical analysis and histological examination of affected teeth, and additional well-designed epidemiological studies -- are needed to confirm the results.

" The findings suggest that amoxicillin use in infancy could carry some heretofore undocumented risk to the developing teeth," they conclude. " While the results of this one study do not warrant recommendations to cease use of Amoxicillin early in life, they do further highlight the need to use antibiotics judiciously, particularly during infancy."

In an editorial accompanying the article, Paul S. Casamassimo, of the Ohio State University College of Dentistry and Columbus Children's Hospital, writes that pediatricians have already reduced their use of Amoxicillin to treat ear infections.

" Looking back through decades on the repeated dental cautions about tetracycline, it took years and alternative drug choices to reshape clinical practice to reduce what was a far more obvious, generalized, and more difficult-to-treat cosmetic problem. If the choice is hearing loss and its sequelae or the possible risk of minor cosmetic disappointment, there is little doubt of what will happen. Frankly, at this point, the association between Amoxicillin use and fluorosis needs further study, as Hong et al have suggested. … Until that time, the best course of action may be what both the medical and dental communities have advocated for a long time -- careful, thoughtful, and appropriate use of both fluoride and antibiotics."

Source: American Medical Association, 2005


XagenaMedicine_2005



Indietro